David is a lawyer and patent agent working at Psygen Industries Ltd., a contract manufacturer focused on providing active pharmaceutical ingredients and research chemicals for use in clinical and non-clinical research of psychedelics. Psygen is focused on manufacturing both classical psychedelics such as LSD, psilocybin, DMT and MDMA, and on manufacturing new chemical entities created by Psygen’s customers. David also works with a small number of clients in the cannabis industry and the psychedelics space through his solo legal practice, R-Group Legal. Through his solo practice, David provides regulatory, intellectual property and commercial advice. He also provides pro bono support to TheraPsil, a non-profit focused on expanding access to psilocybin for Canadians who can benefit from therapeutic use of psilocybin. Prior to working with Psygen and beginning his solo practice, David was a partner in the intellectual property group of a national law firm, where he co-chaired a cannabis and psychedelics focus group alongside a partner practising in capital markets. Prior to attending law school, David completed a PhD in structural biochemistry with a heavy focus on organic chemistry, which has been invaluable in providing well-informed advice relating to technical aspects of both psychedelics and cannabis.
